ScripSanofi’s hopes that itepekimab will follow Dupixent onto the list of approved drugs for chronic obstructive pulmonary disease (COPD) have been hit by a mixed set of results from a pair of late-stage t
ScripBayer’s hopes of catching up with Boehringer Ingelheim’s small molecule HER2 inhibitor zongertinib have been boosted by regulators in the US putting sevabertinib, its same-class candidate for lung can
Pink SheetContract manufacturing of biologics is one of the few weak points in the typically overwhelming advantage the US holds over Europe in bestowing the first approval for new drug products, a Pink Sheet
ScripTherapies ranging from small molecules to immuno-oncology drugs will make appearances at the 2025 American Society of Clinical Oncology meeting. These include drugs that are seen as having the potenti